Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: CPRX

Catalyst Pharmaceuticals, Inc.

Healthcare | Biotechnology

No licensed closing price on file for CPRX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$1.73

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 13:41 UTC.

What Catalyst Pharmaceuticals, Inc. does

This company is a biopharmaceutical firm that licenses, develops, and commercializes medicines for rare and difficult-to-treat diseases. The company currently sells three drugs: FIRDAPSE (for Lambert-Eaton Myasthenic Syndrome), AGAMREE (for rare muscle disease), and FYCOMPA (for epilepsy), supported by a field team of medical professionals and patient support staff. FIRDAPSE is distributed in the U.S. through specialty pharmacies and support programs, with expansion into Canadian and Japanese markets through licensing agreements.

Summarized from Catalyst Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

CPRX no longer appears among SEC's registered filers -- it may have been acquired, merged, or delisted. The figures on this page reflect the company's final filings and are no longer refreshed.

Key facts

Valuation
EPS (TTM)$1.73
Return on equity22.46%

Revenue, margins & earnings

FY2021 Net income: $39MFY2021 Taxes & interest: $13MFY2021 Operating costs: $88M$141MFY2021FY2022 Net income: $83MFY2022 Taxes & interest: $19MFY2022 Operating costs: $112M$214MFY2022FY2023 Net income: $71MFY2023 Taxes & interest: $15MFY2023 Operating costs: $311M$398MFY2023FY2024 Net income: $164MFY2024 Taxes & interest: $31MFY2024 Operating costs: $297M$492MFY2024FY2025 Net income: $214MFY2025 Taxes & interest: $43MFY2025 Operating costs: $331M$589MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-07-17
Most recent filed transactions — July 2026:
  • 2026-07-17Chief Strategy OfficerRestricted Stock UnitsReturned to company-6,855—
  • 2026-07-17Chief Strategy OfficerOptions to purchase common stockReturned to company-143,193—
  • 2026-07-17President and CEORestricted Stock UnitsReturned to company-115,283—
Sign in to see all transactions →

Company news

View all →

Questions this page answers

What does Catalyst Pharmaceuticals, Inc. do?

This company is a biopharmaceutical firm that licenses, develops, and commercializes medicines for rare and difficult-to-treat diseases.

When did CPRX last file with the SEC?

Catalyst Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-08. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 13:41 UTC. This page is also available as JSON at /api/data?ticker=CPRX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CPRX and 5,000+ tickers.

Create a free account — keep CPRX
For your agent
GET /api/data?ticker=CPRX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt